To explore whether the immune signature could predict the immunological phenotype of BCa, we studied our immune signature in a large cohort (IMvigor210) of patients with urothelial carcinoma treated with PD‐L1 inhibitors (atezolizumab). The gene discussed is CD274; the disease is urothelial carcinoma.